How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
Plus, how the industry plans to offset looming patent losses and where to find top stocks.
Audio is streamed directly from the publisher (afp-956310-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.
Why GLP-1 Drugs Are in Demand
Competition Between Novo Nordisk and Eli Lilly
How Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance Coverage
Are Weight Loss Drugs a Threat to Snack Food Stocks?
Big Pharma’s Looming Patent Cliff
How Medicare Negotiations Impact the Pharmaceutical Industry
What is a Biologic Drug?
Upcoming Innovations in the Pharmaceutical Industry
Which BioPharma Drugs Do We Expect to Contract?
Big Pharma’s Five-Year Outlook
Biopharmaceutical Stock Picks
Read about topics from this episode.
2024 Biopharmaceutical Industry Landscape
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
Investment Opportunities in the Biopharma Industry
Obesity Drug Market: The Next Wave of GLP-1 Competition
What to watch from Morningstar.
Is the Fed’s Plan to Avoid a Recession Working?
Don't Overlook These Crucial Parts of Your Retirement Plan
Boating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks
5 Ways to Improve America’s Retirement Savings
Read what our team is writing:
Follow us on social media.
Facebook: https://www.facebook.com/MorningstarInc/
X: https://x.com/MorningstarInc
Instagram: https://www.instagram.com/morningstar...
LinkedIn: https://www.linkedin.com/company/5161/
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.